Citations

Showing 10 of 108119 citations.

Radiation dose and image quality comparison during spine surgery with two different, intraoperative 3D imaging navigation systems
Nachabé, Rami, Strauss, Keith J. , Schueler, Beth A. , Bydon, Mohamad , Schueler, Beth

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 24, 2019 | Volume: 20 | Issue: 2 | Pages: 136-145

10.1002/acm2.12534 | PMID 30677233 Get It

AbstractCareful protocol selection is required during intraoperative three‐dimensional (3D) imaging for spine surgery to manage patient radiation dose and achieve clinical image quality. Radiation dose and image quality of a Medtronic O‐arm commonly used during spine surgery, and a Philips hybrid operating room equipped with XperCT C‐arm 3D cone‐beam CT (hCBCT) are compared. The mobile O‐arm (mCBCT) offers three different radiation dose settings (low, standard, and high), for four different patient sizes (small, medium, large, and extra large). The patient's radiation dose rate is constant during the entire 3D scan. In contrast, C‐CBCT spine imaging uses three different field of views (27, 37, and 48 cm) using automatic exposure control (AEC) that modulates the patient's radiation dose rate during the 3D scan based on changing patient thickness. hCBCT uses additional x‐ray beam filtration. Small, medium, and large trunk phantoms designed to mimic spine and soft tissue were imaged to assess radiation dose and image quality of the two systems. The estimated measured “patient” dose for the small, medium, and large phantoms imaged by the mCBCT considering all the dose settings ranged from 9.4–27.6 mGy, 8.9–33.3 mGy, and 13.8–40.6 mGy, respectively. The “patient” dose values for the same phantoms imaged with hCBCT were 2.8–4.6 mGy, 5.7–10.0 mGy, and 11.0–15.2 mGy. The CNR for the small, medium, and large phantoms was 2.9 to 3.7, 2.0 to 3.0, and 2.5 to 2.6 times higher with the hCBCT system, respectively. Hounsfield unit accuracy, noise, and uniformity of hCBCT exceeded the performance of the mCBCT; spatial resolution was comparable. Added x‐ray beam filtration and AEC capability achieved clinical image quality for intraoperative spine surgery at reduced radiation dose to the patient in comparison to a reference O‐arm system without these capabilities.
The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report
Ebeling, Peter R. , Bauer, Douglas C. , Eastell, Richard , Fink, Howard A , Guañabens, Núria , Kado, Deborah M. , Kallmes, David F. , Katzman, Wendy B. , Rodríguez, Alexander J. , Wermers, Robert A. , Wilson, H Alexander, Bouxsein, Mary , Kallmes, David, Wermers, Robert, Ebeling, Peter R , Bauer, Douglas C , Fink, Howard A , Åkesson, Kristina , Buchbinder, Rachelle , Giangregorio, Lora

Mayo Clinic

Journal of Bone and Mineral Research | January 24, 2019 | Volume: 34 | Issue: 1 | Pages: 3-21

10.1002/jbmr.3653 | PMID 30677181 Get It

ABSTRACT Vertebral augmentation is among the current standards of care to reduce pain in patients with vertebral fractures (VF), yet a lack of consensus regarding efficacy and safety of percutaneous vertebroplasty and kyphoplasty raises questions on what basis clinicians should choose one therapy over another. Given the lack of consensus in the field, the American Society for Bone and Mineral Research (ASBMR) leadership charged this Task Force to address key questions on the efficacy and safety of vertebral augmentation and other nonpharmacological approaches for the treatment of pain after VF. This report details the findings and recommendations of this Task Force. For patients with acutely painful VF, percutaneous vertebroplasty provides no demonstrable clinically significant benefit over placebo. Results did not differ according to duration of pain. There is also insufficient evidence to support kyphoplasty over nonsurgical management, percutaneous vertebroplasty, vertebral body stenting, or KIVA®. There is limited evidence to determine the risk of incident VF or serious adverse effects (AE) related to either percutaneous vertebroplasty or kyphoplasty. No recommendation can be made about harms, but they cannot be excluded. For patients with painful VF, it is unclear whether spinal bracing improves physical function, disability, or quality of life. Exercise may improve mobility and may reduce pain and fear of falling but does not reduce falls or fractures in individuals with VF. General and intervention-specific research recommendations stress the need to reduce study bias and address methodological flaws in study design and data collection. This includes the need for larger sample sizes, inclusion of a placebo control, more data on serious AE, and more research on nonpharmacologic interventions. Routine use of vertebral augmentation is not supported by current evidence. When it is offered, patients should be fully informed about the evidence. Anti-osteoporotic medications reduce the risk of subsequent vertebral fractures by 40–70%. © 2018 American Society for Bone and Mineral Research.
Is It Time to Stop (or Pause) Vertebral Augmentation?
Clarke, B.L. , Khosla, Sundeep , Clarke, Bart L

Mayo Clinic

Journal of Bone and Mineral Research | January 24, 2019 | Volume: 34 | Issue: 1 | Pages: 1-2

10.1002/jbmr.3651 | PMID 30677182 Get It

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Hálfdánarson, Þorvarður R. , Foster, Nathan R. , Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C. , McCullough, Ann E. , Ames, Matthew M. , Jaffe, Jeffrry P., Halfdanarson, Thorvardur R , Alberts, Steven R.

Mayo Clinic

The Oncologist | January 24, 2019 | Volume: 24 | Issue: 5 | Pages: 589-e160

10.1634/theoncologist.2018-0878 | PMID 30679315 Get It

Abstract Lessons Learned Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy. The dual EGFR-directed therapy resulted in increased toxicity. Background Gemcitabine is active in patients with advanced pancreatic adenocarcinoma. The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. Methods Eligible patients with metastatic adenocarcinoma of the pancreas were randomized to either gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A) or the same combination with the addition of panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B). The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, the confirmed response rate, and toxicity. Comparison between arms for the primary endpoint was done with a one-sided log-rank test, and a p value less than .20 was considered statistically significant. Response rate comparison was done with Fisher's exact test. All other reported p values are two-sided. Results A total of 92 patients were randomized, 46 to each arm. The median overall survival was 4.2 months in Arm A and 8.3 months in Arm B (hazard ratio, 0.817; 95% confidence interval [CI], 0.530–1.260; p = .1792). The progression-free survival was 2.0 months in Arm A and 3.6 months in Arm B (hazard ratio, 0.843; 95% CI, 0.555–1.280; p = .4190). A partial confirmed response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (p = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients on Arm B compared with those on Arm A (82.6% vs. 52.2%; p = .0018). Conclusion Dual EGFR-directed therapy resulted in a significant prolongation of overall survival in patients with advanced adenocarcinoma of the pancreas but was associated with substantially increased toxicities. Dual EGFR-directed therapy in combination with gemcitabine alone cannot be recommended for further study, as single-agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.
Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population
Bobo, William V. , Leung, Jonathan G. , Stoppel, Cynthia , Hoel, Robert W. , Chang, Zheng , Lachner, Christian , Chauhan, Mohit , Flowers, L, Brue, Scott M., Frye, Mark A. , Sauver, Jennifer L. St. , Rocca, Walter A. , Sutor, Bruce, Grossardt, Brandon R. , Takahashi, Paul Y. , Flowers, Lee, St Sauver, Jennifer, Leung, Jonathan G , V Bobo, William , St Sauver, Jennifer L , Lapid, Maria I. , Chauhan, Mohit

Mayo Clinic

Pharmacology Research & Perspectives | January 24, 2019 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/prp2.461 | PMID 30693088 Get It

AbstractThe purpose of this study was to estimate the extent of potential antidepressant overprescribing in a geographically defined U.S. population, and to determine the indications and factors that account for it. We conducted a cohort study of new antidepressant prescriptions for elderly residents of Olmsted County, Minnesota, 2005‐2012, using the Rochester Epidemiology Project medical records‐linkage system. Indications for antidepressants were abstracted from health records for all cohort members. Potential antidepressant overprescribing was defined based on regulatory approval, the level of evidence identified from a standardized drug information database, and multidisciplinary expert review. Predictors of potential antidepressant overprescribing were investigated using logistic regression models, stratified by general antidepressant indication (general medical indication, specific psychiatric diagnosis, and non‐specific psychiatric symptoms). Potential antidepressant overprescribing occurred in 24% of 3199 incident antidepressant prescriptions during the study period, and involved primarily newer antidepressants that were prescribed for non‐specific psychiatric symptoms and subthreshold diagnoses. Potential antidepressant overprescribing was associated with nursing home residence, having a higher number of comorbid medical conditions and outpatient prescribers, taking more concomitant medications, having greater use of urgent or acute care services in the year preceding the index antidepressant prescription, and being prescribed antidepressants via telephone, e‐mail, or patient portal. In conclusion, potential antidepressant overprescribing occurred in elderly persons and involved mainly newer antidepressants used for non‐specific psychiatric symptoms and subthreshold diagnoses, and was associated with indicators of higher clinical complexity or severity and with prescribing without face‐to‐face patient contact.
Frequency‐dependent lipid raft uptake at rat diaphragm muscle axon terminals
Porras, Maria A. Gonzalez , Fogarty, Matthew J. , Gransee, Heather M. , Gonzalez Porras, Maria A, Gransee, Heather M , Sieck, Gary C. , Mantilla, Carlos B. , Fogarty, Matthew J

Mayo Clinic

Muscle & Nerve | January 24, 2019 | Volume: 59 | Issue: 5 | Pages: 611-618

10.1002/mus.26421 | PMID 30677149 Get It

ABSTRACT Introduction : In motor neurons, cholera toxin B (CTB) binds to the cell‐surface ganglioside GM1 and is internalized and transported via structurally unique components of plasma membranes (lipid rafts). Methods : Lipid raft uptake by axon terminals adjoining type‐identified rat diaphragm muscle fibers was investigated using CTB and confocal imaging. Results : Lipid raft uptake increased significantly at higher frequency stimulation (80 Hz), compared with lower frequency (20 Hz) and unstimulated (0 Hz) conditions. The fraction of axon terminal occupied by CTB was ∼45% at 0‐ or 20‐Hz stimulation, and increased to ∼65% at 80 Hz. Total CTB fluorescence intensity also increased (∼20%) after 80‐Hz stimulation compared with 0 Hz. Discussion : Evidence of increased lipid raft uptake at high stimulation frequencies supports an important role for lipid raft signaling at rat diaphragm muscle axon terminals, primarily for motor units physiologically activated at the higher frequencies. Muscle Nerve 59:611–611, 2019
Hypertrophic cardiomyopathy and exercise: a need for more information
Joyner, Michael J.

Mayo Clinic

The Journal of Physiology | January 24, 2019 | Volume: 597 | Issue: 5 | Pages: 1225-1226

10.1113/jp277538 | PMID 30673131 Get It

Cell-Free DNA Screening During Pregnancy—Reply
Allyse, Megan , Wick, Myra , Allyse, Megan A

Mayo Clinic

JAMA | January 24, 2019 | Volume: 321 | Issue: 3 | Pages: 309

10.1001/jama.2018.18660 | PMID 30667498 Get It

Insulin deficiency and intranasal insulin alter brain mitochondrial function: a potential factor for dementia in diabetes
Ruegsegger, Gregory N. , Manjunatha, S , Summer, Priska , Gopala, Srinivas , Zabeilski, Piotr, Dasari, Surendra , Vanderboom, Patrick M. , Klaus, Katherine A. , Manjunatha, Shankarappa, Lanza, Ian R. , Nair, K. Sreekumaran

Mayo Clinic

The FASEB Journal | January 24, 2019 | Volume: 33 | Issue: 3 | Pages: 4458-4472

10.1096/fj.201802043r | PMID 30676773 Get It

ABSTRACT Despite the strong association between diabetes and dementia, it remains to be fully elucidated how insulin deficiency adversely affects brain functions. We show that insulin deficiency in streptozotocin‐induced diabetic mice decreased mitochondrial ATP production and/or citrate synthase and cytochrome oxidase activities in the cerebrum, hypothalamus, and hippocampus. Concomitant decrease in mitochondrial fusion proteins and increased fission proteins in these brain regions likely contributed to altered mitochondrial function. Although insulin deficiency did not cause any detectable increase in reactive oxygen species (ROS) emission, inhibition of monocarboxylate transporters increased ROS emission and further reduced ATP production, indicating the causative roles of elevated ketones and lactate in counteracting oxidative stress and as a fuel source for ATP production during insulin deficiency. Moreover, in healthy mice, intranasal insulin administration increased mitochondrial ATP production, demonstrating a direct regulatory role of insulin on brain mitochondrial function. Proteomics analysis of the cerebrum showed that although insulin deficiency led to oxidative post‐translational modification of several proteins that cause tau phosphorylation and neurofibrillary degeneration, insulin administration enhanced neuronal development and neurotransmission pathways. Together these results render support for the critical role of insulin to maintain brain mitochondrial homeostasis and provide mechanistic insight into the potential therapeutic benefits of intranasal insulin.—Ruegsegger, G. N., Manjunatha, S., Summer, P., Gopala, S., Zabeilski, P., Dasari, S., Vanderboom, P. M., Lanza, I. R., Klaus, K. A., Nair, K. S. Insulin deficiency and intranasal insulin alter brain mitochondrial function: a potential factor for dementia in diabetes. FASEB J. 33, 4458–4472 (2019). www.fasebj.org